Talymed® Approved for Medicare Pass-Through Status
April 8, 2013
Marine Polymer Technologies, Inc. (MPT), a leading manufacturer and marketer of advanced wound-care products, is pleased to announce that the Centers for Medicare & Medicaid Services ("CMS") has awarded Talymed® pass-through status through the Ambulatory Payment Classification (APC) 1449 for payments under the Hospital Outpatient Prospective Payment System (OPPS). This code will facilitate reimbursement for the application ofTalymed® when used for Medicare patients with acute and chronic wounds in the hospital outpatient department and ambulatory surgical center settings. According to CMS, specific payment instructions will be made available in the April 2013 OPPS Update.
Diabetic and venous ulcers (as well as other wounds and ulcers) present significant clinical challenges for both patients and providers. For example, between 30 and 50 percent of patients with venous leg ulcers that receive the standard of care remain unhealed after 6 months. Even among healed patients, 26 to 34 percent ultimately have a recurrence within one year. 1,2
Talymed® is a bio-active matrix that is cleared by the US Food and Drug Administration (FDA) for the management of wounds, including diabetic ulcers, venous ulcers, pressure ulcers, ulcers of mixed vascular causes, partial- and full-thickness wounds, second-degree burns, surgical wounds, and other bleeding surface wounds and abrasions. The mechanism of action of Talymed® has been investigated in vitro and in vivo. Increased wound-healing rates occur in response to enhanced angiogenesis and granulation tissue formation, in concert with rapid epithelialization.3
About Marine Polymer Technologies, Inc.
Marine Polymer Technologies (MPT) is a privately-held medical device company that researches, develops and markets technologies for patient hemostasis and wound healing based on a proprietary microalgae-based polymer. In addition to Talymed®, MPT products include SyvekExcel® Vascular Access Hemostasis SystemTM for use following femoral catheterization procedures to assist in obtaining and maintaining hemostasis; the Syvek® NT for use in the local management of bleeding wounds such as vascular access sites, percutaneous catheters or tubes and surgical debridement; and the MRDH® trauma dressing intended for the temporary control of severely bleeding wounds such as surgical wounds (operative, post-operative, donor sites, dermatological, etc.) and traumatic injuries.
1. Kelechi T, Mueller M, Hankin C, et al. J Am Acad Dermatol, 2011 May 25.
2 . Hankin CS, Knispel J, Lopes M, Bronstone A, Maus E. J Manag Care Pharm. 2012 Jun;18(5):375-84.
3. Scherer S, Pietramaggiori G, Matthews J, et al. Ann Surg. 2009 Aug; 250(2):322-30.